Nuvalent Boosts Innovation With Dr. Henry Pelish As Chief Scientific Officer

Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company dedicated to developing precisely targeted therapies for well-established kinase targets in cancer, announced today the promotion of Henry Pelish, Ph.D., to Chief Scientific Officer. Dr. Pelish will continue to lead the discovery and early-stage development efforts in his new role.

James Porter, Ph.D., Chief Executive Officer at Nuvalent said, “This promotion reflects Henry's significant contributions to establishing the cornerstone of our approach at Nuvalent: leveraging a deep expertise in chemistry and structure-based drug design with the goal to deliver meaningful patient impact. Under Henry's leadership, our discovery team has brought forward three novel kinase inhibitors with the aim of delivering on potential best-in-class target product profiles, two of which have demonstrated preliminary clinical proof-of-concept, and continues to advance a robust discovery pipeline. We are pleased to recognize his talent, vision, and dedication towards advancing our mission to discover, develop, and deliver a pipeline of precisely targeted therapies for patients with cancer.”

Dr. Pelish played a key role in founding Nuvalent and became the Biology lead in 2018, where he has been responsible for the discovery and early-stage development of zidesamtinib, NVL-655, and NVL-330, as well as spearheading ongoing research initiatives. With a Ph.D. in chemistry from Harvard University, Dr. Pelish brings over 15 years of expertise in cancer biology, chemical biology, and organic chemistry to his position.

Dr. Pelish added, "The opportunity to take part in building Nuvalent from the ground up has been one of the most rewarding experiences of my career. From the outset, our efforts have focused on solving the limitations of existing therapies, and I am encouraged by all we have been able to achieve thus far. I look forward to continuing to work with my highly dedicated colleagues towards our goal of delivering tangible benefits to patients with cancer.”